Filing Details

Accession Number:
0000921895-19-000500
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-14 21:55:46
Reporting Period:
2019-02-11
Accepted Time:
2019-02-14 21:55:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
727510 Enzon Pharmaceuticals Inc. ENZN Biological Products, (No Disgnostic Substances) (2836) 222372868
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1265094 Jonathan Couchman 630 Fifth Avenue
Suite 2260
New York NY 10020
No No Yes No
1571659 Xstelos Corp. 630 Fifth Avenue
Suite 2260
New York NY 10020
No No Yes No
1737322 Fund Family Couchman 630 Fifth Avenue, Suite 2260
New York NY 10020
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.01 Par Value Acquisiton 2019-02-11 15,500 $0.25 4,697,166 No 4 P Direct
Common Stock, $0.01 Par Value Acquisiton 2019-02-11 10,000 $0.25 4,707,166 No 4 P Direct
Common Stock, $0.01 Par Value Acquisiton 2019-02-11 500 $0.25 4,707,666 No 4 P Direct
Common Stock, $0.01 Par Value Acquisiton 2019-02-11 10,000 $0.25 4,717,666 No 4 P Direct
Common Stock, $0.01 Par Value Acquisiton 2019-02-11 10,000 $0.25 1,569,523 No 4 P Indirect By Xstelos Corp.
Common Stock, $0.01 Par Value Acquisiton 2019-02-11 5,000 $0.25 1,574,523 No 4 P Indirect By Xstelos Corp.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Indirect By Xstelos Corp.
No 4 P Indirect By Xstelos Corp.
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock, $0.01 Par Value 400,000 Indirect By Couchman Family Fund
Footnotes
  1. This Form 4 is filed jointly by Jonathan Couchman ("Mr. Couchman"), Couchman Family Fund (the "Foundation") and Xstelos Corp. ("Xstelos" and, together with Mr. Couchman and the Foundation, the "Reporting Persons"). Each of the Reporting Persons may be deemed to be a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons expressly disclaims beneficial ownership of the Shares reported herein except to the extent of his or its pecuniary interest therein, and this report shall not be deemed to be an admission that any Reporting Person is the beneficial owner of such Shares for purposes of Section 16 or for any other purpose.
  2. Represents Shares owned directly by Xstelos. Mr. Couchman is the controlling shareholder and Chief Executive Officer of Xstelos. By virtue of these relationships, Mr. Couchman may be deemed to beneficially own the Shares owned directly by Xstelos. Mr. Couchman expressly disclaims beneficial ownership of such Shares except to the extent of his pecuniary interest therein.
  3. Represents Shares owned directly by the Foundation. Mr. Couchman is the sole trustee of the Foundation. By virtue of this relationship, Mr. Couchman may be deemed to beneficially own the Shares owned directly by the Foundation, however he has no pecuniary interest in such Shares.